Compare ADMA Biologics Inc (ADMA) vs Expedia Group Inc (EXPE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ADMA Biologics Inc vs Expedia Group Inc — how do they compare? ADMA Biologics Inc trades at $9.81 (market cap $2.18B), while Expedia Group Inc trades at $321.16 (market cap $37.69B). The key difference: Expedia Group Inc is far larger — about 17.3× ADMA Biologics Inc's market cap, and Expedia Group Inc pays a 0.61% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | EXPE | |
|---|---|---|
Market Cap | $2.18B | $37.69B |
Sector | Health | Consumer Cyclical |
52-Week High | $20.38 | $321.07 |
52-Week Low | $7.60 | $188.51 |
Enterprise Value | $2.25B | $36.25B |
Dividend Yield | — | 0.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.90, down 1.59% today, with strong profitability metrics including 64.71% gross margin and 41.9% ROE. Technical indicators show a bullish trend with support at $9-10, though RSI levels suggest overbought conditions. Recent earnings show mixed results with Q4 2025 beating expectations but Q1 and Q2 2026 missing estimates. The stock faces significant legal headwinds with multiple securities fraud lawsuits filed against the company.
Despite strong fundamentals and bullish analyst consensus (88.9% buy ratings), ADMA faces substantial legal risks from ongoing securities litigation that could impact shareholder value. The company's solid profit margins and growth trajectory provide upside potential, but investors should carefully weigh litigation risks against fundamental strength.
Expedia Group (EXPE) trades at $310.68, up 1.34% on the day, with a bullish technical signal supported by moving averages and strong quarterly earnings beats. The company reported Q2 2026 EPS of $5.76, exceeding expectations, driven by 14% revenue growth and robust B2B performance. Valuation metrics include a P/E of 19.54 and P/S of 2.51, with net income margin improving to 12.97% in 2025. Recent news highlights AI integration and raised full-year guidance, reflecting operational strength.
The outlook for EXPE is positive, with earnings momentum and strategic expansions offering upside potential, though high debt levels and travel industry volatility pose risks. Analysts project a consensus price target of $322.95, with 47% buy ratings, indicating cautious optimism. Investors should weigh solid fundamentals against macroeconomic sensitivities affecting travel demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Expedia Group Inc
Expedia is the world's largest online travel agency by bookings, offering services for lodging (75% of total 2021 sales), air tickets (3%), rental cars, cruises, in-destination, and other (15%), and advertising revenue (7%). Expedia operates a number of branded travel booking sites, including Expedia.com, Hotels.com, Travelocity, Orbitz, Wotif, AirAsia, and Vrbo. It has also expanded into travel media with the acquisition of Trivago. Transaction fees for online bookings account for the bulk of sales and profits.
Read more on EXPE →
